Project Optimus elicits the "holistic" benefits of PK/PD modeling of immunotherapy.

Leveraging a heterogeneous dataset, a recent article demonstrated the application of pharmacometric modeling to inform dosing of nivolumab-relatlimab fixed-dose combination in special populations, including adolescents lacking clinical data. Use of model-informed approaches during clinical drug development can be cost effective, ensuring faster access to drugs, thus enhancing patient outcomes.